This HTML5 document contains 115 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00771/identifier/pharmgkb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00771/identifier/kegg-compound/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00771/identifier/bindingdb/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n5http://linked.opendata.cz/resource/drugbank/mixture/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00771/identifier/drugbank/
n18http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB00771/identifier/iuphar/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00771/identifier/guide-to-pharmacology/
admshttp://www.w3.org/ns/adms#
n16http://www.drugs.com/mtm/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00771/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00771/identifier/wikipedia/

Statements

Subject Item
n2:DB00771
rdf:type
n3:Drug
n3:description
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
n3:dosage
n22:271B5D97-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
n3:manufacturer
n12:271B5D94-363D-11E5-9242-09173F13E4C5
owl:sameAs
n18:DB00771 n20:DB00771
dcterms:title
Clidinium
adms:identifier
n8:366 n9:C07853 n10:DB00771 n11:366 n13:50055977 n14:3743 n19:Clidinium n21:PA164781044
n3:mechanismOfAction
Inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites primarily by inhibiting the M1 muscarinic receptors.
n3:packager
n12:271B5D7C-363D-11E5-9242-09173F13E4C5 n12:271B5D7D-363D-11E5-9242-09173F13E4C5 n12:271B5D7A-363D-11E5-9242-09173F13E4C5 n12:271B5D7B-363D-11E5-9242-09173F13E4C5 n12:271B5D80-363D-11E5-9242-09173F13E4C5 n12:271B5D81-363D-11E5-9242-09173F13E4C5 n12:271B5D7E-363D-11E5-9242-09173F13E4C5 n12:271B5D7F-363D-11E5-9242-09173F13E4C5 n12:271B5D82-363D-11E5-9242-09173F13E4C5 n12:271B5D83-363D-11E5-9242-09173F13E4C5 n12:271B5D78-363D-11E5-9242-09173F13E4C5 n12:271B5D79-363D-11E5-9242-09173F13E4C5 n12:271B5D84-363D-11E5-9242-09173F13E4C5 n12:271B5D85-363D-11E5-9242-09173F13E4C5 n12:271B5D88-363D-11E5-9242-09173F13E4C5 n12:271B5D89-363D-11E5-9242-09173F13E4C5 n12:271B5D86-363D-11E5-9242-09173F13E4C5 n12:271B5D87-363D-11E5-9242-09173F13E4C5 n12:271B5D8C-363D-11E5-9242-09173F13E4C5 n12:271B5D8D-363D-11E5-9242-09173F13E4C5 n12:271B5D8A-363D-11E5-9242-09173F13E4C5 n12:271B5D8B-363D-11E5-9242-09173F13E4C5 n12:271B5D90-363D-11E5-9242-09173F13E4C5 n12:271B5D91-363D-11E5-9242-09173F13E4C5 n12:271B5D8E-363D-11E5-9242-09173F13E4C5 n12:271B5D8F-363D-11E5-9242-09173F13E4C5 n12:271B5D92-363D-11E5-9242-09173F13E4C5 n12:271B5D93-363D-11E5-9242-09173F13E4C5
n3:synonym
Bromure de Clidinium Clidinium bromid 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane CLIDINIUM Clidinii Bromidum N-Methyl quinuclidinyl benzilate 3-Hydroxy-1-methylquinuclidinium benzilate ester Bromuro de clidinio
n3:toxicity
Signs of toxicity include confusion, paralytic ileus, urinary hesitancy/retention, and blurred vision.
n3:mixture
n5:271B5D64-363D-11E5-9242-09173F13E4C5 n5:271B5D65-363D-11E5-9242-09173F13E4C5 n5:271B5D62-363D-11E5-9242-09173F13E4C5 n5:271B5D63-363D-11E5-9242-09173F13E4C5 n5:271B5D60-363D-11E5-9242-09173F13E4C5 n5:271B5D61-363D-11E5-9242-09173F13E4C5 n5:271B5D5F-363D-11E5-9242-09173F13E4C5 n5:271B5D74-363D-11E5-9242-09173F13E4C5 n5:271B5D75-363D-11E5-9242-09173F13E4C5 n5:271B5D72-363D-11E5-9242-09173F13E4C5 n5:271B5D73-363D-11E5-9242-09173F13E4C5 n5:271B5D70-363D-11E5-9242-09173F13E4C5 n5:271B5D71-363D-11E5-9242-09173F13E4C5 n5:271B5D6E-363D-11E5-9242-09173F13E4C5 n5:271B5D6F-363D-11E5-9242-09173F13E4C5 n5:271B5D6C-363D-11E5-9242-09173F13E4C5 n5:271B5D6D-363D-11E5-9242-09173F13E4C5 n5:271B5D6A-363D-11E5-9242-09173F13E4C5 n5:271B5D6B-363D-11E5-9242-09173F13E4C5 n5:271B5D68-363D-11E5-9242-09173F13E4C5 n5:271B5D69-363D-11E5-9242-09173F13E4C5 n5:271B5D66-363D-11E5-9242-09173F13E4C5 n5:271B5D67-363D-11E5-9242-09173F13E4C5 n5:271B5D76-363D-11E5-9242-09173F13E4C5 n5:271B5D77-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Sternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche, Inc.
foaf:page
n16:clidinium.html
n3:IUPAC-Name
n4:271B5D9C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5DA2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5DA1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5D9E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5D9F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5DA0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5D9A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5D9B-363D-11E5-9242-09173F13E4C5 n4:271B5D98-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5D99-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5DA8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5DA9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5DA3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5DA4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5DA6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5DA5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5DA7-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
7020-55-5
n3:category
n3:containedIn
n6:271B5D95-363D-11E5-9242-09173F13E4C5 n6:271B5D96-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5DAE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5DB0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5DB1-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5DB2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5DAD-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5DAC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5DAF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5D9D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5DAA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5DAB-363D-11E5-9242-09173F13E4C5